The panel reflects on the most important unanswered questions and future directions in endometrial cancer. Dr. Konecny highlights the promise of molecularly stratified treatment approaches targeting HER2, TROP2, B7-H4, and hormonal signaling pathways, drawing parallels to successes achieved in breast cancer.
Dr. Thaker reviews the immune-related adverse event profile associated with checkpoint inhibitor therapy in endometrial cancer, describing the most commonly encountered toxicities in clinical practice, including hypothyroidism, hyperthyroidism, colitis, and arthralgias.
Dr. Redfern provides a detailed, clinically practical overview of mismatch repair and microsatellite instability testing in endometrial cancer, explaining the mechanistic differences between immunohistochemistry—which assesses protein expression of MLH1, PMS2, MSH2, and MSH6—and next-generation sequencing or PCR-based microsatellite instability testing.
The panel surveys the clinical trial landscape and emerging therapeutic strategies for patients with recurrent endometrial cancer, particularly those who have progressed on frontline checkpoint inhibitor–based therapy.
Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.
New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.
SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.
Dr. Konecny reviews the design and key efficacy findings of the RUBY trial, the first large randomized study to evaluate dostarlimab in combination with carboplatin and paclitaxel as frontline therapy for advanced or recurrent endometrial cancer. He describes the eligibility criteria, dosing schedule, and the striking outcomes observed in both mismatch repair–deficient and mismatch repair–proficient patient populations, including a approximately 70% risk reduction in progression-free survival in the deficient group and a statistically significant 25% risk reduction in the proficient group. Dr. Wenham and Dr. Konecny also contrast the RUBY and NRG-GY018 trial designs. Dr. Redfern then addresses how these results translate to real-world populations, citing evidence presented at ASCO 2025 demonstrating comparable outcomes, and shares her own clinical experience incorporating dostarlimab into routine practice.
Moderator Robert M. Wenham, MD, MS, opens by welcoming panelists Premal H. Thaker, MD, MS, Tiffany M. Redfern, MD, FACOG, and Gottfried E. Konecny, MD, before setting the stage for the discussion. Dr. Thaker reviews the pre-2024 treatment landscape in advanced and recurrent endometrial cancer, including the establishment of paclitaxel plus carboplatin as standard-of-care chemotherapy through GOG 209. She then outlines the pivotal shift brought about by the addition of immune checkpoint inhibitors to chemotherapy, highlighting the RUBY, NRG-GY018, and DUO-E trials and summarizing the FDA approvals that emerged from each. The panel briefly distinguishes the indications across regimens, noting that approval for the durvalumab-plus-olaparib combination was limited to patients with mismatch repair–deficient disease, setting the stage for deeper discussion of individual trial data.
Robert Wenham, MD, MS, FACOG, FACS, discusses the importance of clinical trials in ovarian cancer.
Robert Wenham, MD, MS, FACOG, FACS, discusses the role of antibody-drug conjugates in ovarian cancer.
Robert Wenham, MD, MS, FACOG, FACS, discusses the potential for immunotherapy in ovarian cancer.
Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.
Robert Wenham, MD, MS, FACOG, FACS, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.
Robert M. Wenham, MD, gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses data with intraperitoneal (IP) chemotherapy, dose-dense chemotherapy, and intravenous (IV) chemotherapy in patients with advanced ovarian cancer.
Robert M. Wenham, MD, gynecologic oncologist and chair of the Department of Gynecologic Oncology at Moffitt Cancer Center, sheds light on the debate between neoadjuvant chemotherapy and primary debulking surgery in patients with newly diagnosed, advanced ovarian cancer.
February 24th 2021
June 20th 2022
